Barcelona Liver Bioservices

The complete pre-clinical solution

BLB is a contract research organization that offers cutting-edge research services and consultancy in the field of liver diseases. We provide tailored reliable solutions to our partners for successful strategic decision making.

Research Services


BLB offers you the possibility to test your drug candidates in a human liver
biological system: the unique and
patent-protected ExoLiver platform.

Read more ›

Rodent models

BLB provides research services using top-quality pre-clinical models of liver
disease, including liver cirrhosis,
cholestatic liver disease & NASH.

Read more ›

Liver cells

BLB develops analysis with highly pure and viable rodent and human primary hepatocytes, liver sinusoidal endothelial cells, hepatic stellate cells and Kupffer cells.

Read more ›


BLB gives you the possibility to analyze your favourite gene or protein in liver tissue obtained from rodents and humans.

Read more ›

Organ on a chip

BLB offers high-quality services to create tailored organ on a chip platforms for pre-clinical human disease modelling.

Read more ›

Strategic consultancy

The virtuous combination of having deep experience in both pre-clinical and clinical phases of liver research

Read more ›

Our Values
  • We are innovative, passionate and scientifically curious.

  • We prioritize rigorousness and integrity.

  • We listen our customers, so we provide the best solution for their enquiries.

  • We are committed with our community & the environment.

2 December, 2020

Latest BLB research published in the Journal of Hepatology

Barcelona Liver Bioservices (BLB), CRO specialized in liver diseases, announced today the publication of the manuscript entitled “The pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease” in the peer-reviewed scientific journal Journal of Hepatology. The study describes the pre-clinical research developed in collaboration with Inventiva, a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of NASH and other diseases with unmet medical need.

23 March, 2020

Barcelona Liver Bioservices announces collaboration with GAT Therapeutics

Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in the field of liver diseases, announced today a non-exclusive collaboration with GAT Therapeutics, an early stage biopharma targeting fibrosis and age-related diseases.

1 November, 2019

Barcelona Liver Bioservices announces presentations at the AASLD Liver Meeting 2019.

Barcelona Liver Bioservices (BLB) announced today the presentation of two communications at the annual meeting of the American Association for the Study of the Liver (AASLD), held in Boston, Massachusetts.